Chugai Pharmaceutical
Clinical trials sponsored by Chugai Pharmaceutical, explained in plain language.
A Japanese pharmaceutical company focused on biotech and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets immune overdrive in six rare diseases Results expected Mar 2027 (estimated)
- New hope for celiac sufferers: drug targets gut damage despite strict diet Results expected Jun 2027 (estimated)
-
Can a new drug shrink Hard-to-Treat cancers? an early trial seeks answers
Disease control CompletedThis early-phase trial is testing an experimental drug called SPYK04 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for early signs that SPYK…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New targeted drug shows early promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called SAIL66 in 22 adults with advanced solid tumors that have a specific protein (CLDN6). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. While not a cure, the approach aims to control the…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC